Pharmacokinetics of CAMPATH-1H in BMT patients

By Rebello P   Cwynarski K   Varughese M   Eades A   Apperley JF   Hale G  

Cytotherapy, Vol. 3, Iss. 4, 2001-07 ,pp. : 261-267

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Impact on T-cell depletion and CD34⁺ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G

By Williams R.J.   Clarke E.   Blair A.   Evely R.   Hale G.   Waldmann H.   Brookes S.   Pamphilon D.H.  

Cytotherapy, Vol. 2, Iss. 1, 2000-01 ,pp. : 5-14

Ashgate Publishing Ltd

Access to resources Recommend Favorite

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation

By Kottaridis PD   Milligan DW   Chopra R   Chakraverty RK   Chakrabarti S   Robinson S   Peggs K   Verfuerth S   Pettengell R   Marsh JCW   Schey S   Mahendra P   Morgan GJ   Hale G   Waldmann H   De Elvira MC   Williams CD   Devereux S   Linch DC   Goldstone AH   MacKinnon S  

Cytotherapy, Vol. 3, Iss. 3, 2001-05 ,pp. : 197-201

Ashgate Publishing Ltd

Access to resources Recommend Favorite

CAMPATH-1 antibodies in stem-cell transplantation

By Hale G   Cobbold S   Novitzky N   Bunjes D   Willemze R   Prentice HG   Milligan D   MacKinnon S   Waldmann H  

Cytotherapy, Vol. 3, Iss. 3, 2001-05 ,pp. : 145-164

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience

By Novitzky N   Thomas V   Hale G   Waldmann H  

Cytotherapy, Vol. 6, Iss. 2, 2004-04 ,pp. : 172-181

Ashgate Publishing Ltd

Access to resources Recommend Favorite